What do people think of these new startups seeking funding? Any you think are particularly interesting?
Three Longevity Global members pitched their companies:
Ravi Kota, CEO of AITCare. AITCare is pioneering the future of elder care. With cutting-edge technology and a compassionate approach, we empower care facilities, caregivers, and families to provide exceptional support to older adults. Our AI-driven platform, AITCare-II, detects early-stage symptoms of memory loss and offers a holistic ecosystem for real-time monitoring and personalized engagement. We’re gaining industry recognition with four paid customers, six contracts, and eleven Letters of Intent. Join us in reshaping senior care for a brighter, more compassionate future. https://www.ait.care
Kris Barnes, CEO of LentoBio ​Developing small molecule therapeutics targeting aging damage, with focus on presbyopia. ​Presbyopia is an aging disease which happens to all people around age 40-45, making it among the earliest onset aging diseases with a market value estimated at $9-18B annually. Lento Bio is developing small molecule eyedrops to treat presbyopia by improving the flexibility of the lens, the loss of which is the primary cause of the disorder. Leveraging existing knowledge about crosslinks and aggregates reduction, Lento has identified a lead candidate which significantly improves mouse lens stiffness when given in vivo as an eyedrop, and is currently in the lead optimization phase. ​https://lentobio.com
Nikhil Yadala, CEO of Healome One AI based personalised coach to optimise health and longevity by measuring and slowing down aging, establishing causal relationships of habits on outcomes via easy-to-use D2C self experimentation mobile app and platform. https://www.healome.one
​If you would like to pitch at an event, you can apply… All stages of projects are welcome. You must be a Longevity Global member to pitch. You can apply to join us here: https://longevitygl.org/join/.
Videos of pitches here: (note there is also a transcript available if you want to scroll through quickly)
Elder care is one of the few things that scare my about getting old. So much abuse, or just lack of care. My plan is to just walk out into the desert rather than go to a home.
A company can only be as compassionate as its employees- the weakest link.
Find an elder care facility in a country that respects its elders, like in Thailand.
Western world is so degenerate right now when it comes to taking care of elders. Zero respect. In the Med they care more than other western countries what I’ve heard though. Best bet is somewhere in Asia.
mTORC1 is the single most-validated target in longevity. The mTORC1-inhibitor Rapamycin extends longevity in yeasts, worms, flies, and mice (Lamming et al. 2013). Rapamycin dose-dependently extends longevity in mice (Miller et al. 2014). Using novel technology we identified the first non-Rapalog mTORC1-specific inhibitor Meclizine (Allen et al. 2018). Meclizine has been dosed since 1955 in millions of humans as anti-vertigo and anti-nausea medication, with a lower side-effect profile than rapamycin. Some of Rapamycin’s non-longevity negative side effects are thought to result from its non-specific inhibition of mTORC2 (Lamming et al. 2013). We observe that Meclizine is much more specific than rapamycin, with a 100-fold ratio of mTORC1/mTORC2 selectivity, much superior to rapamycin. We propose this selectivity results from engaging the mTOR target at a different site than Rapalogs. We nominated Meclizine for longevity testing within NIA’s Interventions Testing Program (ITP) in 2018, Meclizine extends longevity in male mice, (Harrison et al., submitted). In addition to Meclizine we have identified other chemical scaffolds that inhibit mTORC1 potently and selectively. In Summary, Beiwe has identified the first non-rapalog mTORC1 inhibitors that extend longevity. These appear to bind mTOR at a distinct site than rapalogs, and are much more mTORC1-specific than rapamycin, and have a lower side-effect profile than rapamycin. Beiwe is optimizing these molecules for maximal potency and reduced side-effect profiles to test as Healthy Aging or Longevity therapeutics.
MonchMonch the micro-sponge that monches the calories
MonchMonch (our current “beta”, launching October 2023)…the micro-sponge that monches the calories; described by the ex-CSO of Mars as “THE HOLY GRAIL OF NUTRITION".
Today’s food tastes good…but it’s not good for your health. Our 100% natural “super fiber” makes food healthier, whilst maintaining the same taste.
Higher dietary fiber content correlates with a reduction in chronic disease. We aim to enable people to live healthier, happier and hence “longer” lives, without the need for diet restrictions.
​If you would like to pitch at an event, you can apply by filling out thisshort form. All stages of projects are welcome. You must be a Longevity Global member to pitch. You can apply to join us here.
Follow us on the platform formerly know as Twitter @LongevityGL
Lento Bio seem like an interesting company just because of the indication they’re targeting. It seems like a huge market. Presbyopia is in some ways one of the first physical signs of aging and decline.
From an investment standpoint the company feels like it’s in a good place to tap into a big market. But I’ve also heard of other pharma companies have shelved similar products, although maybe the particular mechanism wasn’t all that compelling.
